Licensed CAR-T cell manufacturing suites inside cancer hospitals
TL;DR Cellsuite builds and runs GMP cell-processing suites inside large cancer hospitals and makes an already approved Indian CAR-T therapy there, under licence from its owner. Patients get their cells back in about two weeks instead of a month. Product owners and hospitals pay for the capacity.
India now has its own CAR-T therapies for blood cancers, at about ₹30–40 lakh against well over ₹3.5 crore in the US[1][2]. Getting them is still slow, though. In the first 250 real-world patients on India's first CAR-T product, treated at 56 centres, the median wait from cell collection to infusion was 29 days and some waited 102[3].
That's a long time if you have aggressive relapsed lymphoma or leukaemia, and many patients need bridging chemotherapy just to hold on.
Why the wait? Cells travel to one central plant and back. One research firm notes that treatment centres cluster in metros and that families often have to relocate for weeks[1]. A hospital-based academic trial in Vellore cut the wait to nine days[4].
What it does, in regulatory terms: licensed contract manufacture of an approved cell-therapy drug. Cellsuite does not diagnose, select patients or treat. The hospital's haematology team does that. CAR-T products are new drugs under India's NDCT Rules 2019[5], and every manufacturing site needs CDSCO approval and GMP inspection.
Cellsuite fits out an ISO class-7 suite with closed, automated cell-processing machines in two or three high-volume cancer hospitals. It signs a tech-transfer agreement with the owner of an approved CD19 CAR-T, proves that cells made in its suite match those from the central plant, and then runs manufacturing, quality control and release on site.
The seed pitched decentralised, rapid production of immunotherapy as a platform. A startup cannot legally make its own CAR-T at many sites without first getting a product approved, and that's a decade-long drug programme. So I kept the goal of faster treatment closer to the patient and made the company a licensed manufacturer for approved products.
Patients mostly pay for CAR-T themselves, since PM-JAY's ₹5 lakh family cover cannot fund a course[6]. Cellsuite's buyers are businesses, though. Product owners, the Indian CAR-T developers, pay per batch for extra capacity, and hospitals pay a fee or share revenue to offer faster on-site treatment. That Vellore trial put manufacturing cost at US$35,107 per product (about ₹34 L), excluding vector[4], so there's very little margin at today's prices unless volumes grow.
Two Indian CAR-T products are approved - the first in October 2023 and the second in January 2025[1][2]. The second product's maker raised over ₹100 Cr in June 2026 to expand manufacturing[7]. Results from India and abroad in 2025–2026 show point-of-care production working, with vein-to-vein times of 9–12 days[4][8].
Nobody has published a market figure for CAR-T in India, so here's my arithmetic. About 250 patients on the first product in roughly 14 months[3] is around 200 a year, which at ₹30–40 lakh comes to about ₹60–80 Cr a year for one product. For something adjacent, One research firm estimates 42,433 diagnosed prevalent DLBCL cases in India in 2023[1], a pool that sets the ceiling and not the demand.
The first product's developer makes it centrally in Mumbai and allots slots through a coordination unit[3]. The second runs a central GMP plant in Bengaluru[7]. A Vellore teaching hospital makes CAR-T on site as an academic programme and wants to add more locations[4]. A Thai programme made cells in a licensed hospital facility, but its total cost per patient was US$111,231[8], which is a good warning that point-of-care is not automatically cheap. No Indian company yet runs licensed manufacturing nodes for other people's approved products.
| Difficulty | Very hard (84/100) |
| Starting capital | ₹34–58 Cr |
| Time to launch | 24–36 months |
Honestly, everything is hard here. You need GMP suites that pass inspection and staff who can run sterile cell processes on a fixed schedule, and then you need comparability data that convinces both the product owner and CDSCO. Above all you need a licence partner who trusts you with their product.
Yes, heavily. You're manufacturing a new drug, so nothing ships until CDSCO has approved and inspected the site.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
Don't let AI release a batch or make any patient decision. Qualified QA staff release every product and the hospital's haematologists decide treatment.
Want to work out the AI layer for Cellsuite? Talk to Yash →
Here's what can go south -
This is only for a team with cell-therapy manufacturing and regulatory experience, ideally people who have run a GMP suite in India, plus investors with a lot of patience. It isn't a software or services play and I wouldn't pretend otherwise. If you can't get a product owner on board then nothing else matters, so first prove one thing - a signed term sheet from a product owner to transfer its process to your suite.
My estimate is ₹34–58 Cr to launch two or three hospital suites, covering clean rooms, automated machines, skilled staff and validation runs. Expect 24–36 months before the first licensed batch.
Yes. CAR-T products are new drugs, so every manufacturing site needs CDSCO permission and a GMP inspection.
Possibly. Programmes in Thailand and other countries already make cells inside hospitals. Each country regulates cell therapy differently though, so check with your own regulator first.
The free Cellsuite validation kit has the line-by-line capital breakdown, the effort scoring, the drug-licensing and biosafety checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for product owners and hospitals, and 5 assumptions to test. Download the kit →
Thinking about building Cellsuite or something close to it? The make-or-break work is landing a licence partner and a clear CDSCO route for a second manufacturing site, and that's a conversation worth having early. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.